Medtronic Will Study TAVR in Low-Risk Patients with Bicuspid Valves
Indication is to the transcatheter aortic valve replacement (TAVR) market as location is to the real estate business. Although TAVR already represents a $3 billion market globally, the leading TAVR companies say the currently approved indications barely scratches the surface in terms of the true growth potential of the space. This week, just ahead of the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Diego, Medtronic announced that FDA has given the go-ahead for a single-arm study to evaluate the CoreValve Evolut TAVR system in patients with bicuspid aortic valves who are at low risk of s...
Source: MDDI - September 18, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news

Latest Structural Heart issue features research on TAVR and Mitral VIV and VIR procedures
(Cardiovascular Research Foundation) The Cardiovascular Research Foundation (CRF) is pleased to announce that the latest issue of Structural Heart: The Journal of the Heart Team features original research articles on transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis and left ventricular systolic dysfunction, and the safety and efficacy of percutaneous mitral valve-in-valve and valve-in ring procedures. The full issue is now available online. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 7, 2018 Category: International Medicine & Public Health Source Type: news

A Re-Look at Evaluation of the Severity of Aortic Stenosis A Re-Look at Evaluation of the Severity of Aortic Stenosis
A landmark study with far-reaching implications demonstrates that current methods for evaluating the severity of aortic stenosis may introduce clinically significant error.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 4, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Strain May Help in Timing Aortic Stenosis Intervention (CME/CE)
(MedPage Today) -- Registries suggest it reveals early LV dysfunction beyond what LVEF can do (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 15, 2018 Category: Cardiology Source Type: news

JenaValve launches feasibility study of next-gen pericardial TAVR system
JenaValve Technology said today it launched an FDA investigational device exemption cleared early feasibility study of its next generation JenaValve pericardial transcatheter aortic valve replacement system. The newly launched trial will explore the use of the device as a minimally invasive treatment for patients with symptomatic, severe aortic stenosis and symptomatic aortic regurgitation in patients who are considered at extreme or high risk for open surgery. “Both myself and my CUMC colleagues, Dr. Susheel Kodali and Dr. Torsten Vahl, are extremely pleased to be the first U.S. physicians to treat patients wit...
Source: Mass Device - August 3, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Replacement Heart Valves JenaValve Source Type: news

CMS panel votes on volume requirements for TAVR centers
The Center for Medicare and Medicaid Services’ Medicare Evidence Development and Coverage Advisory Committee this week opened itself to comments and voted on volume requirements for new and existing transcatheter aortic valve replacement programs and operators. Panelists heard data from individuals across the healthcare spectrum, and ended up voting in the middle on most of the issues, according to a Medscape report. Voting was done on a one-to-five scale of confidence, with five showing high confidence in the resolution, according to the report. On considering hospitals with no TAVR experience opening new programs, ...
Source: Mass Device - July 27, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Regulatory/Compliance Replacement Heart Valves Centers for Medicare and Medicaid Services (CMS) Source Type: news

Meril Aims for Emerging Markets with its TAVR Device
Yet another company is throwing its hat into the transcatheter aortic valve replacement system (TAVR) market. However, Meril Lifesciences is going a different route than other established firms in the space and is initially targeting emerging markets. Meril has been around for 10 years and has been developing its MyVal TAVR technology for about six of those. The company’s success in TAVR lies around the fact that larger organizations don’t consider emerging markets as the first option. The company said it would seek out approval in India first and eventually make its way to developed markets. “We are posi...
Source: MDDI - July 20, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news

Aortic Stenosis: Then and Now Aortic Stenosis: Then and Now
Renowned cardiologist Dr. Eugene Braunwald, M.D., highlights the major developments in the assessment and management of severe aortic stenosis during the past half-centuryCirculation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 2, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

CMS Will Reconsider Its Stance on TAVR
Centers for Medicare & Medicaid Services (CMS) took an unprecedented stance in 2012 when it decided to cover transcatheter aortic valve replacement (TAVR) with strict restrictions regarding its use in patients with symptomatic aortic stenosis. One of the key issues regarding that CMS decision is that it included specific procedural volume restrictions, limiting the use of TAVR to high-volume hospitals and medical centers. Some doctors have argued that procedural volume is an outdated metric. To understand just how unprecedented the agency's decision on TAVR was six years ago, we look back at this MD+DI story quoti...
Source: MDDI - June 28, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news

JenaValve Keeps Steady Pace in the TAVR Market
JenaValve Technology is making steady progress in the development of its next-generation transcatheter aortic valve replacement (TAVR) system. The Irvine, CA-based company said it has implanted the initial patients in a CE mark study for the treatment of severe aortic regurgitation (AR). The CE mark study is an international, prospective, non-randomized, single-arm trial of the JenaValve Pericardial TAVR System for the treatment of AR in patients who are at increased risk for conventional surgical valve replacement. “Our goal is to enable the treatment of patients with severe aortic regurgitation while avoiding many ...
Source: MDDI - June 21, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

JenaValve launches CE Mark study of next-gen TAVR system
JenaValve Technology said this week it launched a new study of its next-generation pericardial transcatheter aortic valve replacement systems using its Coronatix transfemoral delivery catheter. In the newly launched trial, the Irvine, Calif.-based company will explore the use of the system as a treatment for severe aortic regurgitation in patients who are at high risk for conventional surgical valve replacement. “There is currently no TAVR treatment for severe aortic regurgitation cleared by regulators. These patients do not typically develop calcification at the implant site, so other TAVR valves that rely on t...
Source: Mass Device - June 21, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Catheters Clinical Trials Replacement Heart Valves JenaValve Source Type: news

EuroPCR 2018 Roundup: Edwards reportedly pauses Centera valve EU launch
Edwards Lifesciences’ (NYSE:EW) European launch of its Centera valve has been temporarily paused as the company looks to modify the device’s delivery system, according to a Leerink Partner letter to investors highlighting presentations from the EuroPCR 2018 Annual Meeting. Delivery of the unit and its use in clinical cases are slated to resume during the third quarter, according to the letter, with Edwards claiming there will be no impact on its financial guidance for the year. The Centera valve is designed to be repositionable and retrievable, and is delivered through the use of a 14 French motorized deli...
Source: Mass Device - May 24, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiac Implants Cardiovascular Replacement Heart Valves Edwards Lifesciences Source Type: news

MassDevice EuroPCR 2018 Roundup
Valve Tech Roundup – Transcath heart valves getting safer, seeing expanded use   Abbott touts initial data from Portico TAVR study Abbott (NYSE:ABT) today released 30-day data from a study of its Portico transcatheter aortic valve replacement, touting excellent clinical outcomes and low rates of death, disabling stroke and paravalvular leak. The real-world, multicenter, prospective, single-arm Portico I study aimed to explore the safety and efficacy of the Portico valve with independent adjudication of clinical events and independent echocardiography core-lab analysis. Investigators in the study will follo...
Source: Mass Device - May 22, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Replacement Heart Valves Abbott Edwards Lifesciences Esaote Source Type: news

Treatment with Abbott's Portico ™ Transcatheter Aortic Valve Showed Portico is Safe and Reduces Severe Aortic Stenosis at 30 Days in Real-World Setting
- Data presented at EuroPCR indicated excellent clinical outcomes for Portico in a real-world setting to treat common and life-threatening heart valve disease with minimally invasive option (Source: Abbott.com)
Source: Abbott.com - May 22, 2018 Category: Pharmaceuticals Source Type: news

Detection of the Murmur of Advanced Aortic Stenosis Detection of the Murmur of Advanced Aortic Stenosis
How proficient are physicians at detecting aortic stenosis via ascultation? What role does patient characteristics and clinical context play in their success?Southern Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 26, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Are the Odds Ever in Edwards & #039; Favor in the TAVR Games?
With competition picking up in the transcatheter aortic valve replacement (TAVR) space, it's easy to wonder if Edwards Lifesciences will continue to be the market victor. The company's stock price dipped this week after Edwards posted first-quarter results that fell short of consensus expectations. But to borrow a popular phrase from Suzanne Collins' Hunger Games trilogy, there is still plenty of reason to believe that the odds may be ever in Edwards' favor. Here are the key takeaways from the company's earnings call, as transcribed by Seeking Alpha, along with analyst comments. 1. Medtronic's royalty payment rat...
Source: MDDI - April 25, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news

Rapid Deployment Valve for Aortic Stenosis Ups Stroke Risk
FRIDAY, April 13, 2018 -- For patients with aortic valve stenosis, treatment with a rapid deployment valve (RDV) is associated with increased rates of new-onset pacemaker implantation and disabling stroke, compared with conventional biological... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 13, 2018 Category: Pharmaceuticals Source Type: news

JenaValve Is a Growing Force to be Reckoned with in TAVR
It would be a big mistake to leave JenaValve out of the transcatheter aortic valve replacement (TAVR) market conversation. The Munich, Germany-based company has been biding its time and reaching milestones, in the hopes of obtaining some serious market share in the TAVR space. The small company's latest achievement is successfull enrollment in the CE mark study of the next generation of JenaValve Pericardial TAVR system. “It’s very tricky to develop a TAVR system because it can take several iterations before you can get it right,” Victoria Carr-Brendel, JenaValve CEO, told MD+DI. “We think we ...
Source: MDDI - April 11, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Implants Source Type: news

NOTION: 5-Year TAVR vs SAVR Outcomes Similar in Low-Risk Patients NOTION: 5-Year TAVR vs SAVR Outcomes Similar in Low-Risk Patients
All-cause mortality, MI, and stroke were similar in low-risk patients with severe aortic stenosis who had transcatheter aortic valve replacement and those who had surgery, but 42% of TAVR patients needed pacemakers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 9, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Edwards Eyes Delay for its Sapien 3 Ultra TAVR
Edwards Lifesciences said it is delaying the launch of the Sapien 3 Ultra transcatheter aortic valve replacement (TAVR) System in Europe until later this year. The Irvine, CA-based company said it would refocus on commercialization efforts after it submits data from the 30-patient, single-arm study of the device treating patients at intermediate risk from surgical valve replacement. The study data would help supplement the company’s bid to gain CE mark for the technology. Edwards said the updated timing for the European launch of the Sapien 3 Ultra doesn’t change the company’s sales guidance for 2018...
Source: MDDI - March 22, 2018 Category: Medical Devices Authors: Omar Ford Tags: Implants Source Type: news

Colibri Course Corrects to be Relevant in TAVR
Colibri Heart Valve LLC has started a feasibility study of its second-generation transcatheter aortic valve replacement system that will treat patients with severe aortic stenosis. The Broomfield, CO-based company said it has treated two patients in the study with its redesigned valve. “We spent the last three years modifying our product because the market has changed so drastically from 2012, in both patient indications and also bicuspid valves,” Joseph Horn, president and CEO of Colibri Heart Valve, told MD+DI. “We decided that the product we had was probably not going to be robust enough to satisfy the...
Source: MDDI - March 19, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Implants Source Type: news

TAVR Reasonable for Low-Flow, Low-Gradient Aortic Stenosis (CME/CE)
(MedPage Today) -- Low 30-day mortality observed in high-risk group (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - March 19, 2018 Category: Surgery Source Type: news

Medtronic and Edwards Duel in TAVR Space
A pair of studies support the long-term use of Medtronic’s CoreValve transcatheter aortic valve replacement (TAVR) system. The Dublin-based company unveiled results from both the Nordic Aortic Valve Intervention Trial (NOTION) and the CoreValve U.S. Pivotal Extreme Risk Study at the American College of Cardiology 67th Annual Scientific Session (ACC) this past weekend. NOTION is a physician-initiated trial that studied an all-comers population of 280 patients at least 70 years old. Patients in the trial were randomized to either Surgical Aortic Valve Replacement (SAVR) or TAVR procedures. Join us at the BIOM...
Source: MDDI - March 13, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news

Edwards Adds Bold New Chapter to TAVR Story
Edwards Lifesciences just might have leaped-frogged over some of its competitors in the burgeoning  TAVR market. The undisputed TAVR pioneer has received CE mark for its Centera valve to treat severe, symptomatic aortic stenosis patients at high risk of open-heart surgery. The Edwards Centera valve is repositionable and retrievable and can be delivered through a low-profile, 14-French, motorized delivery system. The company said the device is packaged with the valve fully pre-attached to the delivery system, which helps with simple and rapid device preparation. Network with your colleagues in medtech at ADM&...
Source: MDDI - February 15, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Medical Device Business Source Type: news

Edwards Lifesciences wins CE Mark for Centera TAVR
Edwards Lifesciences (NYSE:EW) said today it won CE Mark approval in the European Union for its self-expanding transcatheter Centera aortic heart valve, with indications for treating symptomatic aortic stenosis patients at high risk of open-heart surgery. The Centera valve is designed to be repositionable and retrievable, and is delivered through the use of a 14 French motorized delivery system in which the valve is pre-attached to the mechanism for quick preparation, the Irvine, Calif.-based company said. “With the Edwards Centera valve, European clinicians and their patients may now benefit from a self-ex...
Source: Mass Device - February 15, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Regulatory/Compliance Replacement Heart Valves Edwards Lifesciences Source Type: news

The Future of TAVI The Future of TAVI
While TAVI has emerged as the established therapy for patients with severe, symptomatic aortic stenosis, there are still challenges that remain, and improvements that can be made.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Cardiac Amyloid Buildup Not Uncommon In TAVR Patients
(MedPage Today) -- Study opens question of interaction between aortic stenosis, amyloid (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 22, 2018 Category: Cardiology Source Type: news

Ashfield are shortlisted for a PM Award
Ashfield Digital & Creative, alongside our colleagues at Watermeadow Medical and our clients at Edwards Lifesciences, are thrilled to announce that we have been shortlisted for a PM Society Award in the Primary Care Campaign category for ‘Listen to the Heart’. A campaign focused on the lifesaving opportunity available to GPs through the early identification of aortic stenosis. Speaking about the collaboration, which led to this campaign, Ashfield Digital & Creative Senior Vice-President Andrew Binns said, “This entry demonstrates the impact that can be achieved when strategic insights and cre...
Source: Ashfield Healthcare News - January 18, 2018 Category: Pharmaceuticals Authors: Daniel Goodwin Tags: Ashfield Source Type: news

Edwards Lifesciences recalls Certitude delivery device for Sapien 3 valve
Edwards Lifesciences (NYSE:EW) is recalling the Certitude delivery device used with its Sapien 3 replacement heart valve on the risk that a molding defect could embolize, the FDA said today. The Sapien 3 is a transcatheter aortic valve replacement designed to treat aortic stenosis. During implantation the valve is crimped to Certitude’s balloon before either transapical or transaortic insertion into the body. The recall, of some lots made between Nov. 22, 2016, and July 10 of last year, is due to a molding overflow defect in the button valve within Certitude’s loader, according to the federal safety watchd...
Source: Mass Device - January 11, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Catheters Recalls Replacement Heart Valves Edwards Lifesciences Source Type: news

3 Reasons TAVR Will Continue to Prosper
The transcatheter aortic valve replacement (TAVR) market has already seen rapid growth, and today represents a $3 billion market globally. But the leading TAVR companies say the current technology and approved indications barely scratches the surface in terms of the true growth potential of the space. Michael Mussallem, CEO of Edwards Lifesciences, told J.P. Morgan Healthcare Conference attendees on Monday that the global TAVR market is expected to exceed $5 billion by 2021, and that number does not include certain indications that are currently being explored, like treatment for patients with asymptomatic aortic...
Source: MDDI - January 9, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news

Impaired Survival With LVEF < 60 Percent in Aortic Stenosis
Poorer outcomes seen for LVEF (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - January 5, 2018 Category: Respiratory Medicine Tags: Cardiology, Nursing, Pathology, Pulmonology, Critical Care, Journal, Source Type: news

' Normal' LVEF: Misnomer in Aortic Stenosis?
(MedPage Today) -- Study shows survival in severe aortic stenosis impaired with LVEF (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 27, 2017 Category: Cardiology Source Type: news

Can Boston Scientific Bounce Back from Lotus Setback?
Boston Scientific shares took a beating Tuesday after the company abruptly backed out of a scheduled appearance at the annual Piper Jaffray healthcare conference in New York. As investors seemed to fear, the sudden change of plans foreshadowed another Lotus setback. The company's stock (NYSE: BSX) dropped 7.5% by market close on Tuesday, slashing Boston Scientific's market cap by about $2.9 billion. About three hours after the close, the company said it had pushed back its previously-reported timelines for re-introducing the Lotus Edge aortic valve system in Europe, and the filing of a final pre-market approval (PMA) modul...
Source: MDDI - November 29, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: Medical Device Business Cardiovascular Source Type: news

Boston Scientific takes a $3B hit on latest Lotus valve delay
Boston Scientific (NYSE:BSX) saw its market capitalization lose $3 billion after yesterday revealing another delay for its Lotus replacement heart valve. The Marlborough, Mass.-based company, which recalled the Lotus transcatheter aortic heart valve in February over issues with its locking mechanism, said it no longer expects the ensuing manufacturing and design specification changes to get the valve back on the market in Europe or allow the final filing in its pre-market approval bid with the FDA by January 2018. “We continue to see value in the unique benefits of the LOTUS Valve platform in treating patients w...
Source: Mass Device - November 29, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Replacement Heart Valves Wall Street Beat Boston Scientific Source Type: news

Afternoon open heart surgery 'leads to fewer complications'
Conclusion This study found evidence of an effect that's worth investigating further to see if there are real differences in heart muscle function and risk of complications from heart surgery at different times of the day. However, there were some limitations: It took place at a single hospital, with a relatively small number of people undergoing operations. The laboratory study found differences in gene activity that suggested the body clock may play a role in making the heart better able to tolerate loss of oxygen and subsequent re-oxygenation. However, there may be other explanations for these differences. For example, ...
Source: NHS News Feed - October 27, 2017 Category: Consumer Health News Tags: Heart/lungs Source Type: news

RAS Blockade After TAVI Tied to Better Outcomes (CME/CE)
(MedPage Today) -- Patients with severe aortic stenosis see reduced all-cause mortality (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - October 26, 2017 Category: Urology & Nephrology Source Type: news

All-Time High for Obesity; Aortic Stenosis AUC; Prognosticating Cardiac Arrest
(MedPage Today) -- Cardiovascular Daily wraps up the top cardiology news of the week (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - October 20, 2017 Category: Pediatrics Source Type: news

TAVR Looms Large in First AUC Document for Severe Aortic Stenosis TAVR Looms Large in First AUC Document for Severe Aortic Stenosis
There are more treatment options than ever before, but guidelines only go so far when the patient is 90-something, frail, and with multiple chronic disorders, for example.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 20, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Appropriate Use Criteria Developed for Aortic Stenosis Tx
SAVR or TAVR appropriate for most patients with symptomatic AS at intermediate or high surgical risk (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 18, 2017 Category: Respiratory Medicine Tags: Cardiology, Nursing, Pulmonology, Surgery, Journal, Source Type: news

First Appropriate Use Criteria for Severe Aortic Stenosis Published (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The American College of Cardiology, the American Heart Association, and nine other medical groups have issued the first-ever appropriate use criteria for treating severe aortic stenosis.The … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 18, 2017 Category: Primary Care Source Type: news

First Appropriate Use Criteria Issued for Severe Aortic Stenosis
(MedPage Today) -- Multi-society guide OKs intervention for most symptomatic cases (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 17, 2017 Category: Primary Care Source Type: news

Shockwave Medical raises $35m for Lithoplasty devices
Shockwave Medical said today that it raised another $35 million for the Lithoplasty devices it’s commercializing to treat blocked arteries. Fremont, Calif.-based Shockwave said it plans to use the new funding, which was led by new backer Fidelity Management & Research, to commercialize its existing devices for treating coronary and peripheral vessels in the U.S. and Europe and to evaluate the Lithoplasty tech in treating aortic valve stenosis. T. Rowe Price Assoc. also participated in the financing, which Shockwave said was an extension of its $45 million Series C round. The Lithoplasty devices are...
Source: Mass Device - October 10, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Funding Roundup Ultrasound Wall Street Beat peripheral Shockwave Medical Source Type: news

Medtronic launches post-market study of CoreValve Evolut Pro heart valve
Medtronic (NYSE:MDT) said today it launched a post-market clinical study of its CoreValve Evolut Pro valve, looking to evaluate performance out to 5 years for the self-expanding transcather aortic valve implantation system. The multi-center, prospective single-arm study aims to enroll 600 patients across 35 European sites to evaluate the safety of the CoreValve Evolut Pro, including all-cause mortality and all stroke at 30 days and clinical performance including valve hemodynamics and paravalvular regurgitation. “We look forward to replicating the excellent clinical outcomes demonstrated by the Evolut Pro valve ...
Source: Mass Device - September 21, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Replacement Heart Valves Medtronic Source Type: news

Medical societies expand collaboration on cardiac registry
The American Society of Nuclear Cardiology (ASNC) and the American Society...Read more on AuntMinnie.comRelated Reading: ASNC, SNMMI advise on cardiac sarcoidosis ASNC releases guidance on MPI in women ASE: Echo protocol finds kids' heart abnormalities Echo groups release guidance on aortic stenosis Echo groups release new stress echo guidelines (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 19, 2017 Category: Radiology Source Type: news

Regular Evaluation Improves Survival in Asymptomatic Severe AS Regular Evaluation Improves Survival in Asymptomatic Severe AS
Patients with asymptomatic severe aortic stenosis followed according to guideline recommendations were more likely to undergo early valve replacement and had improved survival and reduced hospitalization.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 18, 2017 Category: Radiology Tags: Cardiology News Source Type: news

New educational resource to help GPs detect aortic stenosis early
A new interactive educational resource for GPs has been launched to support the early detection of aortic stenosis. (Source: GP Online News)
Source: GP Online News - September 14, 2017 Category: Primary Care Tags: 15.1 Cardiovascular Problems Source Type: news

Do You Listen to Heart Sounds? This May be Another Reason Why You Should.
I’m not sure about you, but when I went to school to become a paramedic (and a nurse for that matter), one thing I never really understood was heart sounds, or heart tones, depending on who taught you. My attempt at learning resorted to scouring textbooks, journals, online editorials, watching clips on YouTube and listening… lots of listening to sound bites from CDs. You know the ones, they come free when you buy a new stethoscope. Instead of turning to digital media, I should’ve been listening to the hearts of my patients. Hindsight is 20/20, especially in this case. All my self-guided education yielded...
Source: JEMS Patient Care - September 12, 2017 Category: Emergency Medicine Authors: Bruce Hoffman, MSN,BSN-RN, NR-P, CFRN Tags: Patient Care Cardiac & Resuscitation Source Type: news

Tall VTE Risk; Frequent Aortic Stenosis Checks;'Sweet Spot' for LVAD Volume
(MedPage Today) -- Cardiovascular Daily wraps up the top cardiology news of the week (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 8, 2017 Category: Cardiology Source Type: news

Close Watch on Aortic Stenosis May Improve Outcomes
(MedPage Today) -- Single-center study supports guideline-based serial evaluations for asymptomatic patients (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 7, 2017 Category: Cardiology Source Type: news

Serial Echos Valuable in Patients with Asymptomatic Severe Aortic Stenosis (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM Patients with asymptomatic severe aortic stenosis who don't get regular evaluations are at increased risk for death and heart failure, according to a retrospective study in … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 7, 2017 Category: Primary Care Source Type: news